Who is sponsoring NCT03239275?

NCT03239275 is sponsored by Ain Shams University.

What drugs are being tested in NCT03239275?

Interventions in NCT03239275: Biocreative therapy.

What condition does NCT03239275 study?

NCT03239275 studies Malocclusion, Angle Class II, Division 1.

Is NCT03239275 still recruiting?

NCT03239275 is currently completed. Last updated 16 January 2019.

Last reviewed 2019-01-16 · How we verify

NCT03239275

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Evaluation of Bio-creative Therapy for En Masse Retraction of the Maxillary Anterior Teeth

Completed NA Last updated 16 January 2019

What this trial tests

NA trial testing Biocreative therapy in Malocclusion, Angle Class II, Division 1 in 30 participants. Completed in 30 September 2018.

Timeline

17 January 2016

Primary endpoint
30 April 2018

30 September 2018

Quick facts

Lead sponsor	Ain Shams University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	17 January 2016
Primary completion	30 April 2018
Estimated completion	30 September 2018

Drugs / interventions tested

Biocreative therapy

Conditions studied

Malocclusion, Angle Class II, Division 1 — all drugs for Malocclusion, Angle Class II, Division 1 →

Sponsor

Ain Shams University

Who can join

Adults 18 to 25, female only, with Malocclusion, Angle Class II, Division 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the effectiveness and efficiency of labial versus lingual biocreative therapy in achieving en masse retraction of the maxillary anterior teeth in subjects with class II malocclusion requiring upper first premolar extraction.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Type of tooth movement during <i>en masse</i> retraction of the maxillary anterior teeth using labial versus lingual biocreative therapy in adults: A randomized clinical trial.
Sadek MM, Sabet NE, Hassan IT. · · 2019 · cited 8× · PMID 31815106 · DOI 10.4041/kjod.2019.49.6.381

Verify or expand the search:

Other Ain Shams University trials

Trials by the same sponsor.

NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03239275 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
Last refreshed: 16 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03239275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing